SLC5A2 and familial primary hypomagnesemia: These findings presented here expand the current understanding of SGLT2 inhibitors in the management of hypomagnesemia, while laying the foundation to pursue larger clinical investigation to establish a role for SGLT2 inhibition in the treatment of hypomagnesemia.